Anti-CV2/CRMP5 Paraneoplastic Chorea Effectively Managed with Intravenous Amantadine

BACKGROUND: Paraneoplastic chorea is typically a subacute progressive hyperkinetic movement disorder. The mainstay of treatment is managing the underlying neoplasm. However, the clinical course may be variable, and effective symptomatic management can precede the start of cancer treatment. CASE REPO...

Descripción completa

Detalles Bibliográficos
Autores principales: Ha, Jongmok, Na, Boo Suk, Ahn, Jong Hyeon, Kim, Minkyeong, Kim, Jae Woo, Lee, Jae Hyeok, Cho, Jin Whan, Kim, Ji Sun, Youn, Jinyoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia University Libraries/Information Services 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790010/
https://www.ncbi.nlm.nih.gov/pubmed/31656691
http://dx.doi.org/10.7916/tohm.v0.701
Descripción
Sumario:BACKGROUND: Paraneoplastic chorea is typically a subacute progressive hyperkinetic movement disorder. The mainstay of treatment is managing the underlying neoplasm. However, the clinical course may be variable, and effective symptomatic management can precede the start of cancer treatment. CASE REPORT: A 63-year-old man presented with insidious onset, slowly progressive generalized chorea for 1 year, later diagnosed as anti-CV2/CRMP5 autoantibody positive paraneoplastic chorea. His chorea was markedly improved with intravenous amantadine. DISCUSSION: In patients with anti-CV2/CRMP5 autoantibody-related chorea, sequential follow-up of brain magnetic resonance imaging reveals progression from active inflammation to atrophy. Our report highlights the efficacy of intravenous amantadine in paraneoplastic chorea.

Ejemplares similares